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Background: The effect of Ticagrelor (TG) compared to clopidogrel (CLP) on high platelet reactivity (HPR) during maintenance therapy (MT) is 
unknown.
Methods: We analyzed data from ONSET/OFFSET study and RESPOND study in 127 patients with stable coronary artery disease (CAD) during 
75mg/day CLP and 90 mg bid TG maintenance therapy. We determined the frequency of HPR based on previously published cutpoints associated 
with ischemic risk- >59% 20uM ADP-induced platelet aggregation by light transmittance aggregometry, >235 platelet reaction units (PRU) by 
VerifyNow P2Y12 assay and >50% platelet reactivity index (PRI) by vasodilator stimulated phosphorotein phosphorylation (VASP-P) assay. All patients 
were on 75-100mg/day aspirin therapy.
Results: CLP maintenance therapy was associated with high frequency of HPR compared TG (Table).
Conclusions: During ticagrelor maintenance therapy in CAD patients, HPR is rare as compared to clopidogrel maintenance therapy. The reduction 
in patients below the platelet reactivity threshold for risk may in part explain the results of the PLATO trial. 
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